Deutsche Bank analyst Jan Koch maintained a Hold rating on DocMorris (DOCM – Research Report) today and set a price target of CHF25.00. The ...

Full Year 2024 Results Key Financial Results Revenue: CHF1.03b (up 6.5% from FY 2023). Net ...

Although online pharmacies have also had a way to redeem e-prescriptions for a year now, DocMorris is still recording losses.

DocMorris shares plunged after it posted a full-year loss on higher marketing costs to boost its digital prescription sales in Germany. In European early morning trade, shares of DocMorris fell 21% to ...

UBS analyst Sebastian Vogel maintained a Sell rating on DocMorris (DOCM – Research Report) today and set a price target of CHF16.00. The ...

CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Frauenfeld, 13 March 2025These written materials or the ...

By way of indication, for the 2024 financial year DocMorris is expecting: an increase of more than 10% in external revenue (including e-prescriptions); an improvement in adjusted EBITDA to between ...

Every investor in DocMorris AG (VTX:DOCM) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 72% to be precise, is institutions ...

Legal defeat for DocMorris: The European Court of Justice (ECJ) has declared broad German discount bans for online pharmacies to be essentially compatible with EU law. According to a ruling by the ...

Investing.com -- Shares of DocMorris, the Switzerland-listed online pharmacy, saw a steep decline in early European trading, falling 21% to 16.60 Swiss francs.

The BGH must now decide on the AKNR's appeal. DocMorris will continue to leverage the opportunities of digitalization and the growth of e-prescriptions in Germany. Background of the Case Between 2012 ...